ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2224

Increased Immune Complex Levels in Children with Juvenile Dermatomyositis Are Not Associated with Levels of Von Willebrand Factor Antigen, C4, Duration of Illness, Disease Activity Score, or the Absolute NK Count

Lauren M. Pachman1, Akadia Kachaochana2, Gabrielle A. Morgan3, Dong Xu2, Chiang-Ching Huang4 and Anil K. Chauhan5, 1Division of Pediatric Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL, 2Program of Excellence in Cure-Juvenile Myositis (JM) Research, Stanley Manne Children’s Research Institute, affiliated with Ann & Robert H. Lurie Children’s Hospital of Chicago, Chicago, IL, 3Stanley Manne Children’s Research Institute, affiliated with Ann & Robert H. Lurie Children’s Hospital of Chicago, Cure JM Myositis Center, Chicago, IL, 4Zilber School of Public Health, University of Wisconsin at Milwaukee, Milwaukee, WI, 5Rheumatology, Saint Louis University, St. Louis, MO

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Immune response and inflammatory myositis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Muscle Biology, Myositis and Myopathies: Immunological Aspects of Inflammatory Myopathy

Session Type: Abstract Submissions (ACR)

Background/Purpose:

A potential  mechanism for the vasculopathy of Juvenile Dermatomyositis (JDM), the most common pediatric inflammatory myopathy, has been attributed to complement mediated immune complex damage to endothelial cells with subsequent release of von Willebrand Factor Antigen (vWF:Ag).  Although we previously reported that JDM C4 levels were  decreased in  30% patients, associated with decreased gene copy number  [Arthritis Rheum, 2012;  64(S10):S826], the role of C4 in this process has not been documented.   The purpose of this cross-sectional study was to determine the concentration of immune complexes in JDM sera compared with healthy controls and their association with levels of C4, duration of illness, disease activity scores, vWF:Ag , and absolute number of natural killer cells (NKs)– previously found to be decreased in active disease in 55.7% of JDM.

Methods:

62 children with definite JDM and 20 healthy controls were enrolled and their sera were obtained for immune complex measurement. Among the JDM patients, 29 had normal levels of C4 (21 girls and 8 boys; mean age 14.7±6.8 years) and 32 had low C4 (22 girls and 10 boys, mean age 15.0±3.8 years).  The healthy control group was composed of 11 girls and 9 boys, mean age 12.5±3.5 years. Immune complex level, measured as an aggregated human γ-globulin equivalent, was determined by ELISA. The association of immune complex levels with clinical variables was determined:  disease activity scores (DAS, skin, muscle, total score), duration of untreated disease (DUD), and  vWF:Ag.  ANOVA was used to test the difference of immune complex levels among low, normal C4, and control groups. The Tukey post-hoc was used to test the pair-wise mean difference.

Results:  

The immune complex level in pediatric healthy controls was 317±332.4 μg/mL (n=20) (AHG equivalent), 506±347 μg/mL in JDM with low C4 (n=32) and 534±350 μg/mL in JDM with normal C4 (n=29).  The immune complex levels in JDM with low or normal C4 was significantly higher than that in healthy controls (p=0.01). However, there was no difference in the immune complex levels between children with JDM with low C4 and JDM with normal C4 levels (p=0.99). Furthermore, no significant correlation was observed between immune complex levels and a range of clinical features, including duration between disease onset and first treatment (p=0.99), DAS skin (p=0.14), DAS muscle (p=0.15), DAS total (p=0.25), level of vWF:Ag  (p=0.86), or  between  immune complex level and the absolute NK count (p=0.29) among the patients with JDM.

Conclusion:  

We conclude that that immune complex levels are increased in children with JDM irrespective of C4 levels and are not associated with disease duration, activity or evidence of vascular damage. It is not known if these immune complexes are antigenic, or if they play a role in the initiation or perpetuation of disease.


Disclosure:

L. M. Pachman,
None;

A. Kachaochana,
None;

G. A. Morgan,
None;

D. Xu,
None;

C. C. Huang,
None;

A. K. Chauhan,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/increased-immune-complex-levels-in-children-with-juvenile-dermatomyositis-are-not-associated-with-levels-of-von-willebrand-factor-antigen-c4-duration-of-illness-disease-activity-score-or-the-absol/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology